Morgan Stanley Keeps Their Hold Rating on BioNTech SE (BNTX)
Morgan Stanley Sticks to Their Hold Rating for BioNTech SE (BNTX)
Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Reiterating Buy on BioNTech Amid Strategic Growth and Upcoming Catalysts
Critical Insights From BioNTech Analyst Ratings: What You Need To Know
BioNTech Analyst Ratings
Analysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)
Buy Rating on BioNTech SE Amidst Undervaluation and Strong Pipeline Prospects
Evercore ISI Starts BioNTech With In Line Rating, $100 Price Target
BioNTech Analyst Ratings
Analysts Conflicted on These Healthcare Names: BioNTech SE (BNTX), Xenon (XENE) and BioLife Solutions (BLFS)
HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating
Deutsche Numis Reaffirms Their Hold Rating on BioNTech SE (BNTX)